These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

683 related items for PubMed ID: 21459307

  • 1. Identification, pharmacologic considerations, and management of prostatitis.
    Schiller DS, Parikh A.
    Am J Geriatr Pharmacother; 2011 Feb; 9(1):37-48. PubMed ID: 21459307
    [Abstract] [Full Text] [Related]

  • 2. Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome: a randomized, placebo controlled trial.
    Cheah PY, Liong ML, Yuen KH, Teh CL, Khor T, Yang JR, Yap HW, Krieger JN.
    J Urol; 2003 Feb; 169(2):592-6. PubMed ID: 12544314
    [Abstract] [Full Text] [Related]

  • 3. [Alpha-blockers and bioflavonoids in men with chronic nonbacterial prostatitis (NIH-IIIa): a prospective, placebo-controlled trial].
    Lü M, Zhao ST, Wang SM, Shi BK, Fan YD, Wang JZ.
    Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Feb; 25(2):169-72. PubMed ID: 15132876
    [Abstract] [Full Text] [Related]

  • 4. Pharmacotherapy strategies in chronic prostatitis/chronic pelvic pain syndrome management.
    Murphy AB, Nadler RB.
    Expert Opin Pharmacother; 2010 Jun; 11(8):1255-61. PubMed ID: 20429665
    [Abstract] [Full Text] [Related]

  • 5. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.
    Naslund MJ, Miner M.
    Clin Ther; 2007 Jan; 29(1):17-25. PubMed ID: 17379044
    [Abstract] [Full Text] [Related]

  • 6. A placebo-controlled comparison of the efficiency of triple- and monotherapy in category III B chronic pelvic pain syndrome (CPPS).
    Tuğcu V, Taşçi AI, Fazlioğlu A, Gürbüz G, Ozbek E, Sahin S, Kurtuluş F, Cek M.
    Eur Urol; 2007 Apr; 51(4):1113-7; discussion 1118. PubMed ID: 17084960
    [Abstract] [Full Text] [Related]

  • 7. [Feasibility of alpha-blockers in chronic category III prostatitis].
    Altarac S, Cindro V, Radović N, Rajković Z, Belina S.
    Lijec Vjesn; 2011 Apr; 133(5-6):177-80. PubMed ID: 21888082
    [Abstract] [Full Text] [Related]

  • 8. α-blockers, antibiotics and anti-inflammatories have a role in the management of chronic prostatitis/chronic pelvic pain syndrome.
    Thakkinstian A, Attia J, Anothaisintawee T, Nickel JC.
    BJU Int; 2012 Oct; 110(7):1014-22. PubMed ID: 22471591
    [Abstract] [Full Text] [Related]

  • 9. Comparison of results after fluoroquinolones and combination therapies in type IIIA chronic prostatitis.
    Altintas R, Oguz F, Beytur A, Ediz C, Gunes A, Ozer A.
    Actas Urol Esp; 2013 Oct; 37(10):619-24. PubMed ID: 23768504
    [Abstract] [Full Text] [Related]

  • 10. Safety and efficacy of levofloxacin 750 mg for 2 weeks or 3 weeks compared with levofloxacin 500 mg for 4 weeks in treating chronic bacterial prostatitis.
    Paglia M, Peterson J, Fisher AC, Qin Z, Nicholson SC, Kahn JB.
    Curr Med Res Opin; 2010 Jun; 26(6):1433-41. PubMed ID: 20394471
    [Abstract] [Full Text] [Related]

  • 11. Role of alpha1-blockers in chronic prostatitis syndromes.
    Nickel JC.
    BJU Int; 2008 Mar; 101 Suppl 3():11-6. PubMed ID: 18307680
    [Abstract] [Full Text] [Related]

  • 12. Treatment for chronic prostatitis/chronic pelvic pain syndrome: levofloxacin, doxazosin and their combination.
    Jeong CW, Lim DJ, Son H, Lee SE, Jeong H.
    Urol Int; 2008 Mar; 80(2):157-61. PubMed ID: 18362485
    [Abstract] [Full Text] [Related]

  • 13. A randomized, placebo controlled, multicenter study to evaluate the safety and efficacy of rofecoxib in the treatment of chronic nonbacterial prostatitis.
    Nickel JC, Pontari M, Moon T, Gittelman M, Malek G, Farrington J, Pearson J, Krupa D, Bach M, Drisko J, Rofecoxib Prostatitis Investigator Team.
    J Urol; 2003 Apr; 169(4):1401-5. PubMed ID: 12629372
    [Abstract] [Full Text] [Related]

  • 14. Treatment of chronic prostatitis/chronic pelvic pain syndrome with tamsulosin: a randomized double blind trial.
    Nickel JC, Narayan P, McKay J, Doyle C.
    J Urol; 2004 Apr; 171(4):1594-7. PubMed ID: 15017228
    [Abstract] [Full Text] [Related]

  • 15. Multidisciplinary approach to prostatitis.
    Magri V, Boltri M, Cai T, Colombo R, Cuzzocrea S, De Visschere P, Giuberti R, Granatieri CM, Latino MA, Larganà G, Leli C, Maierna G, Marchese V, Massa E, Matteelli A, Montanari E, Morgia G, Naber KG, Papadouli V, Perletti G, Rekleiti N, Russo GI, Sensini A, Stamatiou K, Trinchieri A, Wagenlehner FME.
    Arch Ital Urol Androl; 2019 Jan 18; 90(4):227-248. PubMed ID: 30655633
    [Abstract] [Full Text] [Related]

  • 16. Antimicrobial therapy for chronic bacterial prostatitis.
    Perletti G, Marras E, Wagenlehner FM, Magri V.
    Cochrane Database Syst Rev; 2013 Aug 12; 2013(8):CD009071. PubMed ID: 23934982
    [Abstract] [Full Text] [Related]

  • 17. Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double-blind, placebo-controlled, pilot study.
    Mehik A, Alas P, Nickel JC, Sarpola A, Helström PJ.
    Urology; 2003 Sep 12; 62(3):425-9. PubMed ID: 12946740
    [Abstract] [Full Text] [Related]

  • 18. Phenotypically directed multimodal therapy for chronic prostatitis/chronic pelvic pain syndrome: a prospective study using UPOINT.
    Shoskes DA, Nickel JC, Kattan MW.
    Urology; 2010 Jun 12; 75(6):1249-53. PubMed ID: 20363491
    [Abstract] [Full Text] [Related]

  • 19. Anti-nanobacterial therapy for men with chronic prostatitis/chronic pelvic pain syndrome and prostatic stones: preliminary experience.
    Shoskes DA, Thomas KD, Gomez E.
    J Urol; 2005 Feb 12; 173(2):474-7. PubMed ID: 15643213
    [Abstract] [Full Text] [Related]

  • 20. [Classification, diagnosis and treatment of prostatitis syndrome].
    Krhen I, Skerk V, Schönwald S, Mareković Z.
    Lijec Vjesn; 2002 Feb 12; 124(3-4):89-98. PubMed ID: 18956827
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.